The Selective JAK1/3-Inhibitor R507 Mitigates Obliterative Airway Disease Both With Systemic Administration and Aerosol Inhalation.

MLA

Deuse, Tobias, et al. “The Selective JAK1/3-Inhibitor R507 Mitigates Obliterative Airway Disease Both With Systemic Administration and Aerosol Inhalation.” Transplantation, vol. 100, no. 5, May 2016, pp. 1022–31. EBSCOhost, https://doi.org/10.1097/TP.0000000000001110.

APA

Deuse, T., Hua, X., Stubbendorff, M., Spin, J. M., Neofytou, E., Taylor, V., Chen, Y., Park, G., Fink, J. B., Renne, T., Kiefmann, M., Kiefmann, R., Reichenspurner, H., Robbins, R. C., & Schrepfer, S. (2016). The Selective JAK1/3-Inhibitor R507 Mitigates Obliterative Airway Disease Both With Systemic Administration and Aerosol Inhalation. Transplantation, 100(5), 1022–1031. https://doi.org/10.1097/TP.0000000000001110

Chicago

Deuse, Tobias, Xiaoqin Hua, Mandy Stubbendorff, Joshua M Spin, Evgenios Neofytou, Vanessa Taylor, Yan Chen, et al. 2016. “The Selective JAK1/3-Inhibitor R507 Mitigates Obliterative Airway Disease Both With Systemic Administration and Aerosol Inhalation.” Transplantation 100 (5): 1022–31. doi:10.1097/TP.0000000000001110.